Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1878

1.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

André T, Vernerey D, Im SA, Bodoky G, Buzzoni R, Reingold S, Rivera F, McKendrick J, Scheithauer W, Ravit G, Fountzilas G, Yong WP, Isaacs R, Österlund P, Liang JT, Creemers GJ, Rakez M, Van Cutsem E, Cunningham D, Tabernero J, de Gramont A.

Ann Oncol. 2020 Feb;31(2):246-256. doi: 10.1016/j.annonc.2019.12.006. Epub 2019 Dec 18.

PMID:
31959341
2.

A comparison of rolling averages versus discrete time epochs for assessing the worst-case scenario locomotor demands of professional soccer match-play.

Ferraday K, Hills SP, Russell M, Smith J, Cunningham DJ, Shearer D, McNarry M, Kilduff LP.

J Sci Med Sport. 2020 Jan 9. pii: S1440-2440(19)30574-2. doi: 10.1016/j.jsams.2020.01.002. [Epub ahead of print]

PMID:
31937507
3.

Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.

Turkes F, Carmichael J, Cunningham D, Starling N.

Gastroenterol Res Pract. 2019 Dec 18;2019:7698786. doi: 10.1155/2019/7698786. eCollection 2019. Review.

4.

Assessing the whole-match and worst-case scenario locomotor demands of international women's rugby union match-play.

Sheppy E, Hills SP, Russell M, Chambers R, Cunningham DJ, Shearer D, Heffernan S, Waldron M, McNarry M, Kilduff LP.

J Sci Med Sport. 2019 Dec 20. pii: S1440-2440(19)31251-4. doi: 10.1016/j.jsams.2019.12.016. [Epub ahead of print]

PMID:
31882327
5.

Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells.

Carotenuto P, Hedayat S, Fassan M, Cardinale V, Lampis A, Guzzardo V, Vicentini C, Scarpa A, Cascione L, Costantini D, Carpino G, Alvaro D, Ghidini M, Trevisani F, Te Poele R, Salati M, Ventura S, Vlachogiannis G, Hahne JC, Boulter L, Forbes SJ, Guest R, Cillo U, Said-Huntingford I, Begum R, Smyth E, Michalarea V, Cunningham D, Rimassa L, Santoro A, Roncalli M, Kirnkin V, Clarke P, Workman P, Valeri N, Braconi C.

Hepatology. 2019 Dec 26. doi: 10.1002/hep.31094. [Epub ahead of print]

PMID:
31879968
6.

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.

Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A.

Pancreas. 2020 Jan;49(1):62-75. doi: 10.1097/MPA.0000000000001455.

PMID:
31856081
7.

MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.

Khakoo S, Carter PD, Brown G, Valeri N, Picchia S, Bali MA, Shaikh R, Jones T, Begum R, Rana I, Wotherspoon A, Terlizzo M, von Loga K, Kalaitzaki E, Saffery C, Watkins D, Tait D, Chau I, Starling N, Hubank M, Cunningham D.

Clin Cancer Res. 2020 Jan 1;26(1):183-192. doi: 10.1158/1078-0432.CCR-19-1996. Epub 2019 Dec 18.

PMID:
31852830
8.

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J.

Health Technol Assess. 2019 Dec;23(64):1-88. doi: 10.3310/hta23640.

9.

Reversible and Selective CO2 to HCO2- Electrocatalysis near the Thermodynamic Potential.

Cunningham DW, Barlow JM, Velasquez RS, Yang J.

Angew Chem Int Ed Engl. 2019 Dec 17. doi: 10.1002/anie.201913198. [Epub ahead of print]

PMID:
31846551
10.

R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.

Kühnl A, Peckitt C, Patel B, Ardeshna KM, Macheta MP, Radford J, Johnson R, Paneesha S, Barton S, Chau I, Begum R, Valeri N, Wotherspoon A, Du Y, Zerizer I, Cunningham D.

Ann Hematol. 2020 Jan;99(1):105-112. doi: 10.1007/s00277-019-03842-4. Epub 2019 Nov 27.

PMID:
31776726
11.

The future of CPD for general practitioners, registered pharmacy staff and general practice nurses in Scotland - qualitative responses from a national survey.

Cunningham DE, Luty S, Alexander A, Waqa V, Zlotos L.

Educ Prim Care. 2019 Nov 19:1-8. doi: 10.1080/14739879.2019.1690400. [Epub ahead of print]

PMID:
31744397
12.

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M.

J Immunother Cancer. 2019 Nov 18;7(1):309. doi: 10.1186/s40425-019-0769-8.

13.

The influence of a CSA Educational Intervention for International Medical Graduate General Practice Trainees - A Qualitative Study.

Cunningham DE, Fahd A, Lee K.

Educ Prim Care. 2019 Nov 12:1-2. doi: 10.1080/14739879.2019.1689853. [Epub ahead of print] No abstract available.

PMID:
31713466
14.

Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.

Khan K, Valeri N, Dearman C, Rao S, Watkins D, Starling N, Chau I, Cunningham D.

Crit Rev Oncol Hematol. 2019 Nov;143:153-163. doi: 10.1016/j.critrevonc.2019.09.001. Epub 2019 Sep 7. Review.

PMID:
31678702
15.

DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.

Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee MH, Ooi WF, Qamra A, Inam I, Hewitt LC, So JB, Koh V, Nankivell MG, Langley RE, Allum WH, Cunningham D, Rozen SG, Yong WP, Grabsch HI, Tan P.

Eur J Cancer. 2019 Dec;123:48-57. doi: 10.1016/j.ejca.2019.09.016. Epub 2019 Oct 23.

PMID:
31655359
16.

Neutrophil extracellular traps drive inflammatory pathogenesis in malaria.

Knackstedt SL, Georgiadou A, Apel F, Abu-Abed U, Moxon CA, Cunnington AJ, Raupach B, Cunningham D, Langhorne J, Krüger R, Barrera V, Harding SP, Berg A, Patel S, Otterdal K, Mordmüller B, Schwarzer E, Brinkmann V, Zychlinsky A, Amulic B.

Sci Immunol. 2019 Oct 18;4(40). pii: eaaw0336. doi: 10.1126/sciimmunol.aaw0336.

17.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SA, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A.

Mol Cancer Ther. 2019 Oct 16. pii: molcanther.0466.2019. doi: 10.1158/1535-7163.MCT-19-0466. [Epub ahead of print]

PMID:
31619463
18.

Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center.

Georgiou A, Khakoo S, Edwards P, Minchom A, Kouvelakis K, Kalaitzaki E, Nobar N, Calamai V, Ifijen M, Husson O, Watkins D, Rao S, Chau I, Cunningham D, Starling N.

Cancers (Basel). 2019 Oct 14;11(10). pii: E1558. doi: 10.3390/cancers11101558.

19.

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

Davidson M, Aronson LI, Howard-Reeves J, Bryant H, Cutts RJ, Hulkki-Wilson S, Kouvelakis K, Kalaitzaki E, Watkins D, Starling N, Rao S, Cardenosa ML, Begum R, Rana I, Lazaro-Alcausi R, Terlizzo M, Wotherspoon A, Brown G, Swansbury J, Lord CJ, Cunningham D, Chau I, Chong IY.

Eur J Cancer. 2019 Nov;122:12-21. doi: 10.1016/j.ejca.2019.09.003. Epub 2019 Oct 10.

PMID:
31606655
20.

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma.

Fong CYK, Burke E, Cunningham D, Starling N.

Gastroenterol Res Pract. 2019 Sep 5;2019:7135437. doi: 10.1155/2019/7135437. eCollection 2019. Review.

21.

Accepting or rejecting qualitative education research: what are our expectations as editors?

Scallan S, Cunningham D.

Educ Prim Care. 2019 Sep;30(5):261-262. doi: 10.1080/14739879.2019.1669493. No abstract available.

PMID:
31578945
22.

Elevated Preoperative Hemoglobin A1c Associated with Increased Wound Complications in Diabetic Patients Undergoing Primary, Open Carpal Tunnel Release.

Cunningham DJ, Baumgartner RE, Federer AE, Richard MJ, Mithani SK.

Plast Reconstr Surg. 2019 Oct;144(4):632e-638e. doi: 10.1097/PRS.0000000000006023.

PMID:
31568301
23.

Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.

Davidson M, Wagner AD, Kouvelakis K, Nanji H, Starling N, Chau I, Watkins D, Rao S, Peckitt C, Cunningham D.

Eur J Cancer. 2019 Nov;121:40-47. doi: 10.1016/j.ejca.2019.08.010. Epub 2019 Sep 19.

PMID:
31542640
24.

Practice-Based Small Group Learning (PBSGL) in Scotland: the past, the present and the future.

Cunningham DE, Zlotos L.

Educ Prim Care. 2019 Nov;30(6):337-341. doi: 10.1080/14739879.2019.1666662. Epub 2019 Sep 17.

PMID:
31526319
25.

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC.

J Clin Oncol. 2019 Dec 10;37(35):3392-3400. doi: 10.1200/JCO.19.01124. Epub 2019 Sep 12.

PMID:
31513484
26.

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.

Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, Campbell F, Valle JW, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ting Y, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Lerch MM, Mayerle J, Tjaden C, Strobel O, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer.

JAMA Surg. 2019 Sep 4. doi: 10.1001/jamasurg.2019.3337. [Epub ahead of print]

PMID:
31483448
27.

ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.

Khakoo S, Chau I, Pedley I, Ellis R, Steward W, Harrison M, Baijal S, Tahir S, Ross P, Raouf S, Ograbek A, Cunningham D; ACORN investigators.

Clin Colorectal Cancer. 2019 Dec;18(4):280-291.e5. doi: 10.1016/j.clcc.2019.07.003. Epub 2019 Jul 11.

PMID:
31451367
28.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.

PMID:
31398081
29.

Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies.

Butters O, Young K, Cunningham D, Chau I, Starling N.

Front Oncol. 2019 Jul 16;9:618. doi: 10.3389/fonc.2019.00618. eCollection 2019. Review.

30.

Can we see what is invisible? The role of MRI in the evaluation and management of patients with pathological nipple discharge.

Zacharioudakis K, Kontoulis T, Vella JX, Zhao J, Ramakrishnan R, Cunningham DA, Mufti RA, Leff DR, Thiruchelvam P, Hogben K, Hadjiminas DJ.

Breast Cancer Res Treat. 2019 Nov;178(1):115-120. doi: 10.1007/s10549-019-05321-w. Epub 2019 Jul 27.

31.

General practice recruitment - a survey of awareness and influence of the Scottish Targeted Enhanced Recruitment Scheme (TERS).

Lee K, Cunningham DE.

Educ Prim Care. 2019 Sep;30(5):295-300. doi: 10.1080/14739879.2019.1639554. Epub 2019 Jul 17.

PMID:
31315543
32.

Bilateral Contralaterally Controlled Functional Electrical Stimulation Reveals New Insights Into the Interhemispheric Competition Model in Chronic Stroke.

Cunningham DA, Knutson JS, Sankarasubramanian V, Potter-Baker KA, Machado AG, Plow EB.

Neurorehabil Neural Repair. 2019 Sep;33(9):707-717. doi: 10.1177/1545968319863709. Epub 2019 Jul 18.

PMID:
31315515
33.

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M.

Cancer Cell. 2019 Jul 8;36(1):35-50.e9. doi: 10.1016/j.ccell.2019.05.013.

34.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group.

Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4.

35.

The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.

Salati M, Caputo F, Cunningham D, Marcheselli L, Spallanzani A, Rimini M, Gelsomino F, Reggiani-Bonetti L, Andrikou K, Rovinelli F, Smyth E, Baratelli C, Kouvelakis K, Kalaitzaki R, Gillbanks A, Michalarea V, Cascinu S, Braconi C.

Eur J Cancer. 2019 Aug;117:84-90. doi: 10.1016/j.ejca.2019.05.030. Epub 2019 Jul 2.

36.

Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer.

Anandappa G, Cunningham D.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1447. [Epub ahead of print] No abstract available.

PMID:
31268483
37.

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.

Allum WH, Smyth EC, Blazeby JM, Grabsch HI, Griffin SM, Rowley S, Cafferty FH, Langley RE, Cunningham D.

Br J Surg. 2019 Aug;106(9):1204-1215. doi: 10.1002/bjs.11184. Epub 2019 Jul 3.

38.

Reevaluation of the body mass estimate for the KNM-ER 5428 Homo erectus talus.

Cunningham DL, Rogers MV, Wescott DJ, McCarthy RC.

Am J Phys Anthropol. 2019 Sep;170(1):148-155. doi: 10.1002/ajpa.23898. Epub 2019 Jul 3.

PMID:
31268179
39.

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.

Stewart A, Coker EA, Pölsterl S, Georgiou A, Minchom AR, Carreira S, Cunningham D, O'Brien ME, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U.

Mol Cancer Ther. 2019 Aug;18(8):1396-1404. doi: 10.1158/1535-7163.MCT-18-0727. Epub 2019 Jul 1.

PMID:
31262731
40.

Elevated Preoperative Hemoglobin A1c Associated with Increased Wound Complications in Diabetic Patients undergoing Primary, Open Carpal Tunnel Release.

Cunningham DJ, Baumgartner RE, Federer AE, Richard MJ, Mithani SK.

Plast Reconstr Surg. 2019 Jun 27. doi: 10.1097/PRS.0000000000006023. [Epub ahead of print]

PMID:
31261261
41.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

Smyth EC, Rowley S, Cafferty FH, Allum W, Grabsch HI, Stenning S, Wotherspoon A, Alderson D, Crosby T, Mansoor W, Waters JS, Neville-Webbe H, Darby S, Dent J, Seymour M, Thompson J, Sothi S, Blazeby J, Langley RE, Cunningham D.

JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1179. [Epub ahead of print]

42.

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.

Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I.

Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5.

PMID:
31199501
43.

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2019 Jul;38(28):5746. doi: 10.1038/s41388-019-0835-1.

PMID:
31147600
44.

CPD preferences and activities of general practitioners, registered pharmacy staff and general practice nurses in NHS Scotland - a questionnaire survey.

Cunningham DE, Alexander A, Luty S, Zlotos L.

Educ Prim Care. 2019 Jul;30(4):220-229. doi: 10.1080/14739879.2019.1617644. Epub 2019 May 30.

PMID:
31145862
45.

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.

Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft SY, Rana I, Begum R, Assiotis I, Matthews N, Rao S, Watkins D, Chau I, Cunningham D, Starling N, Gerlinger M.

Cancers (Basel). 2019 May 27;11(5). pii: E736. doi: 10.3390/cancers11050736.

46.

Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.

Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor RT, Del Rio M, Koo SL, Tan WS, Sclafani F, Begum R, Teixeira Mendes LS, Martineau P, Scarpa A, Cervantes A, Tan IB, Cunningham D, Sadanandam A.

Sci Rep. 2019 May 21;9(1):7665. doi: 10.1038/s41598-019-43492-0.

47.

Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer.

Qiu S, Nikolaou S, Fiorentino F, Rasheed S, Darzi A, Cunningham D, Tekkis P, Kontovounisios C.

Horm Cancer. 2019 Jun;10(2-3):128-135. doi: 10.1007/s12672-019-00364-3. Epub 2019 May 15.

48.

International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis.

Scott AJ, Alexander JL, Merrifield CA, Cunningham D, Jobin C, Brown R, Alverdy J, O'Keefe SJ, Gaskins HR, Teare J, Yu J, Hughes DJ, Verstraelen H, Burton J, O'Toole PW, Rosenberg DW, Marchesi JR, Kinross JM.

Gut. 2019 Sep;68(9):1624-1632. doi: 10.1136/gutjnl-2019-318556. Epub 2019 May 15.

49.

Comparison of Tibiotalocalcaneal Arthrodeses Using a Sustained Dynamic Compression Nail Versus Nondynamized Nails.

Steele JR, Kildow BJ, Cunningham DJ, Dekker TJ, DeOrio JK, Easley ME, Nunley JA, Parekh SG, Adams SB.

Foot Ankle Spec. 2019 Apr 25:1938640019843332. doi: 10.1177/1938640019843332. [Epub ahead of print]

PMID:
31018671
50.

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M.

J Immunother Cancer. 2019 Apr 15;7(1):101. doi: 10.1186/s40425-019-0575-3.

Supplemental Content

Loading ...
Support Center